Table 1.
Baseline characteristics of the cohort and split by nephrectomy pre and post systemic therapy.
| Characteristic | Nephrectomy before systemic therapy | No nephrectomy before systemic therapy | Overall | p | |
|---|---|---|---|---|---|
| Total: n (%) | 153 (42.9) | 204 (57.1) | 357 (100%) | ||
| Age at systemic therapy: median (IQI) | 62.0 (55.0–71.0) | 64.0 (55.0–70.2) | 63.0 (55.0–71.0) | 0.536 | |
| Sex: n (%) | Male | 100 (65.4) | 127 (62.3) | 227 (63.6) | 0.623 |
| Female | 53 (34.6) | 77 (37.7) | 130 (36.4) | ||
| Median eGFR before systemic therapy: median (IQI) | 70.6 (56.6–84.9) | 79.0 (61.4–96.0) | 74.6 (58.3–91.9) | <0.001 | |
| Microalbuminuria before systemic therapy: n (%) | Yes | 35 (57.4) | 35 (55.6) | 70 (56.5) | 0.981 |
| No | 26 (42.6) | 28 (44.4) | 54 (43.5) | ||
| Macroalbuminuria before systemic therapy: n (%) | Yes | 6 (9.8) | 5 (7.9) | 11 (8.9) | 0.955 |
| No | 55 (90.2) | 58 (92.1) | 113 (91.1) | ||
| Regime class: n (%) | ICI monotherapy | * | 7 (3.4) | * | 0.081 |
| VSPI monotherapy | 138 (90.2) | 164 (80.4) | 302 (84.6) | ||
| Dual ICI | * | 14 (6.9) | * | ||
| VSPI + ICI combination therapy | 8 (5.2) | 19 (9.3) | 27 (7.6) | ||
| Metastatic cancer at diagnosis: n (%) | Yes | 25 (16.3) | 94 (46.1) | 119 (33.3) | <0.001 |
| No | 128 (83.7) | 110 (53.9) | 238 (66.7) | ||
| Diabetes before systemic therapy: n (%) | Yes | 21 (13.7) | 29 (14.2) | 50 (14.0) | 0.999 |
| No | 132 (86.3) | 165 (85.8) | 307 (86.0) |
Proportions of micro- and macroalbuminuria are reported for those that had quantification by urinary albumin or protein–creatinine ratio. n number, IQI Interquartile interval.
*In this table, data points and totals representing fewer than 5 records have been suppressed and replaced with an asterisk to protect patient confidentiality.